CompletedNCT01524497
Trazodone Extended-Release or Placebo for Depression
About this title
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Read the official source — NCT01524497This study evaluated the safety and effectiveness of Trazodone for people with depression.
Medication studyAges 18–65China
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Trazodone for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- ChangshaSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateNovember 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 382
- Sponsor
- Lee's Pharmaceutical Limited
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01524497
- Official title
Show the full official title
A Clinical Study on Efficacy And Safety of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression A Multicenter, Randomized, Double-Blind, Parallel Controlled Study
Get this study by email
Recruitment & locations
CompletedChangsha
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Trazodone for people with depression.
Who is behind this study?
The study sponsor is Lee's Pharmaceutical Limited, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Trazodone and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
